publication . Article . Other literature type . 2013

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

Mireille Toebes; Sam Behjati; Dris El Atmioui; Ton N. M. Schumacher; Daisy Philips; John B. A. G. Haanen; Can Keşmir; Ron M. Kerkhoven; Laura J.A. van Dijk; Henk Hilkmann; ...
Open Access
  • Published: 10 Nov 2013 Journal: Journal of Clinical Oncology, volume 31, pages e439-e442 (issn: 0732-183X, eissn: 1527-7755, Copyright policy)
  • Publisher: American Society of Clinical Oncology (ASCO)
The evidence for T-cell–mediated regression of human cancers such as non–small-cell lung carcinoma, renal cell carcinoma, and—in particular—melanoma after immunotherapy is strong. Anti-CTLA4 (ipilimumab) treatment has been approved for treatment of meta-static melanoma,1 and antibody-mediated blockade of PD-1, a second inhibitory receptor on T cells, has shown highly encouraging results in early clinical trials.2,3 Although the clinical activity of these treatments is apparent, it is still unknown which T-cell reactivities are involved in immunotherapy-induced cancer regression.4 T-cell reactivity against nonmutated tumor-associated self-antigens has been analyz...
free text keywords: Cancer Research, Oncology, Article, Ataxia telangiectasia and Rad3 related, Immunology, Melanoma, medicine.disease, medicine, business.industry, business, Epitope, Immunotherapy, medicine.medical_treatment, Cancer, Ipilimumab, medicine.drug, Carcinoma, Antigen
Any information missing or wrong?Report an Issue